[go: up one dir, main page]

AR074061A1 - Inhibidores de s1p liasa para el tratamiento de la malaria cerebral y formulacion farmaceutica - Google Patents

Inhibidores de s1p liasa para el tratamiento de la malaria cerebral y formulacion farmaceutica

Info

Publication number
AR074061A1
AR074061A1 ARP090104142A ARP090104142A AR074061A1 AR 074061 A1 AR074061 A1 AR 074061A1 AR P090104142 A ARP090104142 A AR P090104142A AR P090104142 A ARP090104142 A AR P090104142A AR 074061 A1 AR074061 A1 AR 074061A1
Authority
AR
Argentina
Prior art keywords
hydrogen
cerebral malaria
liasa
inhibitors
treatment
Prior art date
Application number
ARP090104142A
Other languages
English (en)
Inventor
Constance Ann Marjory Finney
Stephen Chris Pappas
Tamas Oravecz
Kevin Charles Kain
Brown Philip Manton
Original Assignee
Lexicon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lexicon Pharmaceuticals Inc filed Critical Lexicon Pharmaceuticals Inc
Publication of AR074061A1 publication Critical patent/AR074061A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Reivindicacion 1: Uso de un inhibidor de la S1P liasa en la elaboracion de un medicamento para tratar, manejar y/o prevenir la malaria cerebral. Reivindicacion 4: El uso de una cualquiera de las reivindicaciones 1-3 en donde el inhibidor de la S1P liasa es un compuesto de la formula: 1 o una sal farmacéuticamente aceptable del mismo, en donde: R1 es hidrogeno, alquilo o arilo; R3 es OR3a, NHC(O)R3a, NHSO2R3a o hidrogeno; cada R3a es de manera independiente hidrogeno o alquilo, arilo, alquilarilo, arilalquilo, heteroalquilo, heterociclo, alquilheterociclo o heterocicloalquilo, opcionalmente sustituidos con halo: R6 es OR6a o OC(O)R6a; R7 es OR7a o OC(O)R7a; R8 es OR8a o OC(O)R8a; R9 es hidrogeno, CH2OR9a o CH2OC(O)R9a; y cada R6a, R7a, R8a y R9a es, de manera independiente, hidrogeno o alquilo inferior. Reivindicacion 7: El uso de una cualquiera de las reivindicaciones 1-3, en donde el inhibidor de la S1P liasa es un compuesto de la formula: 2 o una sal farmacéuticamente aceptable del mismo, en donde: A es un heterociclo opcionalmente sustituido; R5 es OR5a o OC(O)R5a; R6 es OR6a, o OC(O)R6a; R7 es OR7a o OC(O)R7a; R8 es hidrogeno, CH2OR8a o CH2OC(O)R8a; y cada uno de R5a, R6a, R7a y R8a es, de manera independiente, hidrogeno o alquilo inferior.
ARP090104142A 2008-10-31 2009-10-27 Inhibidores de s1p liasa para el tratamiento de la malaria cerebral y formulacion farmaceutica AR074061A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10998208P 2008-10-31 2008-10-31
US10998708P 2008-10-31 2008-10-31

Publications (1)

Publication Number Publication Date
AR074061A1 true AR074061A1 (es) 2010-12-22

Family

ID=41480156

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090104142A AR074061A1 (es) 2008-10-31 2009-10-27 Inhibidores de s1p liasa para el tratamiento de la malaria cerebral y formulacion farmaceutica

Country Status (12)

Country Link
US (1) US20100113530A1 (es)
EP (1) EP2367551A1 (es)
JP (1) JP2012507547A (es)
CN (1) CN102196808A (es)
AR (1) AR074061A1 (es)
AU (1) AU2009308832A1 (es)
CA (1) CA2741838A1 (es)
CL (1) CL2009002018A1 (es)
PE (1) PE20100372A1 (es)
TW (1) TW201022254A (es)
UY (1) UY32215A (es)
WO (1) WO2010051353A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3782702A1 (en) * 2019-08-21 2021-02-24 AC BioScience SA Compounds and use thereof for the treatment of infectious diseases and cancer
WO2025027051A1 (en) * 2023-07-31 2025-02-06 Ab Science Sphingosine-1-phosphate lyase inhibitors for use in the treament of neurodegenerative diseases

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1260155B (it) * 1992-08-03 1996-03-28 Fidia Spa Uso terapeutico della fosforil-l-serina-n-acil-sfingosina
US7649098B2 (en) * 2006-02-24 2010-01-19 Lexicon Pharmaceuticals, Inc. Imidazole-based compounds, compositions comprising them and methods of their use
AU2007334436A1 (en) * 2006-12-15 2008-06-26 Abbott Laboratories Novel oxadiazole compounds
TW200838497A (en) * 2006-12-21 2008-10-01 Abbott Lab Sphingosine-1-phosphate receptor agonist and antagonist compounds
WO2008124210A1 (en) * 2007-02-14 2008-10-16 Emory University Methods and compositions for treating or preventing infection using leukocyte sequestration agents
TW200848029A (en) * 2007-03-01 2008-12-16 Lexicon Pharmaceuticals Inc Heterocyclic compounds, compositions comprising them and methods of their use

Also Published As

Publication number Publication date
CL2009002018A1 (es) 2010-08-20
WO2010051353A1 (en) 2010-05-06
US20100113530A1 (en) 2010-05-06
AU2009308832A1 (en) 2010-05-06
CN102196808A (zh) 2011-09-21
EP2367551A1 (en) 2011-09-28
TW201022254A (en) 2010-06-16
JP2012507547A (ja) 2012-03-29
CA2741838A1 (en) 2010-05-06
UY32215A (es) 2010-05-31
PE20100372A1 (es) 2010-06-01

Similar Documents

Publication Publication Date Title
PH12018501807A1 (en) Pyrazolopyrrolidine derivatives and their use in the treatment of diseas
SA519410865B1 (ar) مركب حلقي شبيه بكُومارين بوصفه مثبط mek واستخدامه
GEAP202014726A (en) Cyclic di-nucleotide compounds as sting agonists
PH12017501326A1 (en) Tgf-� inhibitors
MX2020006599A (es) Composiciones y metodos para el tratamiento de trastornos en el sistema nervioso central.
AR124662A2 (es) Formulaciones inmunosupresoras
EA038122B9 (ru) Ингибитор поверхностного антигена вируса гепатита b
MX2014012454A (es) Derivados de imidazotiadiazol como inhibidores del receptor 4 activado de proteasa (par4) para el tratamiento de agregacion plaquetaria.
PH12015500719A1 (en) Gdf-8-inhibitors
MX2015016421A (es) Derivados de pirazolo-pirrolidin-4-ona como inhibidores de bet y su uso en el tratamiento de enfermedades.
MX2020001717A (es) Inhibidores macrociclicos de mcl-1 y metodos de uso.
MX2015008975A (es) Analogos de tiadiazol y metodos para el tratamiento de afecciones relacionadas con deficiencia del gen de supervivencia de las neuronas motoras (smn).
MY148609A (en) Polycyclic indazole derivatives and their use as erk inhibitors for the treatment of cancer
PH12016501355A1 (en) Bicyclic heterocyclic derivatives as bromodomain inhibitors
PH12019501198A1 (en) Tetracyclic heterocycle compounds useful as hiv integrase inhibitors
NZ616806A (en) Pharmaceutical compositions comprising sulbactam and beta-lactamase inhibitor
MX2020011652A (es) Derivados de piridazina 1,4-disustituida, y su uso para el tratamiento de afecciones relacionadas con la deficiencia de smn.
MX2016006667A (es) Derivados de pirrolo-pirrolona y su uso como inhibidores.
GEP20125415B (en) Imidazole derivatives as kinesin spindle protein inhibitors (eg-5)
MX2021010106A (es) Inhibidores de la via de respuesta al estres integrada.
MX2015016425A (es) Derivados de pirazolo-pirrolidin-4-ona y su uso en el tratamiento de enfermedades.
SA519402103B1 (ar) 1,6-naphthyridine مشتقات 1، 6 نفثيرايدين CDK4/6 على شكل مثبط
BRPI0920605A8 (pt) Composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, método para o tratamento ou profilaxia de infecção pelo hiv ou para o tratamento, profilaxia, ou retardo no início ou progressão da aids em um paciente em necessidade deste.
NZ752587A (en) Lsd1 inhibitors and medical uses thereof
MX2019006449A (es) Compuestos heterociclicos triciclicos utiles como inhibidores de la integrasa del virus de inmunodeficiencia humana (vih).

Legal Events

Date Code Title Description
FB Suspension of granting procedure